Are psychiatric comorbidities and associated cognitive functions related to treatment response to methylphenidate in boys with attention-deficit/hyperactivity disorder?

Mandy H Chan,1 Patrick WL Leung,2 Ting-pong Ho,3 Se-fong Hung,4 Chi-chiu Lee,5 Chun-pan Tang,5 Ka-chai Cheung,2 Fung-yee Ching,2 Fefe HK Chan,6 Lu-hua Chen,2 Merce Garcia-Barcelo,7 Pak-chung Sham3 1Department of Clinical Psychology, Kowloon Hospital, Hospital Authority, 2Department of Psychology, T...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chan MH, Leung PW, Ho TP, Hung SF, Lee CC, Tang CP, Cheung KC, Ching FY, Chan FH, Chen LH, Garcia-Barcelo M, Sham PC
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	ADHD psychiatric comorbidities cognitive functions treatment response methylphenidate (MPH) Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/2922c1da2bff49bfb3fde3cafe1bbe4e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2922c1da2bff49bfb3fde3cafe1bbe4e
record_format	dspace
spelling	oai:doaj.org-article:2922c1da2bff49bfb3fde3cafe1bbe4e2021-12-02T06:51:33ZAre psychiatric comorbidities and associated cognitive functions related to treatment response to methylphenidate in boys with attention-deficit/hyperactivity disorder?1178-2021https://doaj.org/article/2922c1da2bff49bfb3fde3cafe1bbe4e2017-04-01T00:00:00Zhttps://www.dovepress.com/are-psychiatric-comorbidities-and-associated-cognitive-functions-relat-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Mandy H Chan,1 Patrick WL Leung,2 Ting-pong Ho,3 Se-fong Hung,4 Chi-chiu Lee,5 Chun-pan Tang,5 Ka-chai Cheung,2 Fung-yee Ching,2 Fefe HK Chan,6 Lu-hua Chen,2 Merce Garcia-Barcelo,7 Pak-chung Sham3 1Department of Clinical Psychology, Kowloon Hospital, Hospital Authority, 2Department of Psychology, The Chinese University of Hong Kong, 3Department of Psychiatry, University of Hong Kong, 4Department of Psychiatry, The Chinese University of Hong Kong, 5Department of Psychiatry, Kwai Chung Hospital, Hospital Authority, 6Department of Clinical Psychology, Alice Ho Mui Ling Nethersole Hospital, Hospital Authority, 7Department of Surgery, University of Hong Kong, Hong Kong, People’s Republic of China Background: Methylphenidate (MPH) has been found to be an effective medication for attention-deficit/hyperactivity disorder (ADHD). However, there are neither consistent nor sufficient findings on whether psychiatric comorbidities and associated cognitive functions of ADHD are related to treatment response to MPH in ADHD children.Objectives: This study investigated whether psychiatric comorbidities, IQ, and neurocognitive deficits are related to treatment response to MPH in ADHD children. In some ways, it is preferable to have a drug that the effectiveness of which to a disorder is not affected by its associated cognitive functions and psychiatric comorbidities. On the other hand, it is likely that the baseline symptom severity of ADHD is associated with the effectiveness of MPH treatment on the symptoms post treatment.Methods: A total of 149 Chinese boys (aged 6–12 years) with ADHD, combined type, and normal IQ participated in this study. Assessment of ADHD symptom severity was conducted pre and post MPH treatment, while assessment of psychiatric comorbidities, IQ, and neurocognitive deficits was performed in a non-medicated condition. Treatment response was defined as the ADHD symptom severity post MPH treatment.Results: Results indicated that MPH treatment was effective, significantly improving the ADHD condition. Yet, comorbid disorders, IQ, and neurocognitive deficits were not related to MPH treatment response on ADHD symptoms. These findings indicated that the effectiveness of MPH was not affected by psychiatric comorbidities and associated cognitive functions of ADHD. Instead, as expected, it was the baseline symptom severity that was mainly related to the treatment response, ie, the milder the baseline condition, the better the treatment response.Conclusion: The current findings positively endorse the widespread clinical use of MPH for treating ADHD. It improves the behavioral symptoms of ADHD regardless of varying psychiatric comorbidities, IQ, and neurocognitive deficits. Keywords: ADHD, psychiatric comorbidities, cognitive functions, treatment response, methylphenidateChan MHLeung PWHo TPHung SFLee CCTang CPCheung KCChing FYChan FHChen LHGarcia-Barcelo MSham PCDove Medical PressarticleADHDpsychiatric comorbiditiescognitive functionstreatment responsemethylphenidate (MPH)Neurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 13, Pp 1071-1080 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	ADHD psychiatric comorbidities cognitive functions treatment response methylphenidate (MPH) Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	ADHD psychiatric comorbidities cognitive functions treatment response methylphenidate (MPH) Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Chan MH Leung PW Ho TP Hung SF Lee CC Tang CP Cheung KC Ching FY Chan FH Chen LH Garcia-Barcelo M Sham PC Are psychiatric comorbidities and associated cognitive functions related to treatment response to methylphenidate in boys with attention-deficit/hyperactivity disorder?
description	Mandy H Chan,1 Patrick WL Leung,2 Ting-pong Ho,3 Se-fong Hung,4 Chi-chiu Lee,5 Chun-pan Tang,5 Ka-chai Cheung,2 Fung-yee Ching,2 Fefe HK Chan,6 Lu-hua Chen,2 Merce Garcia-Barcelo,7 Pak-chung Sham3 1Department of Clinical Psychology, Kowloon Hospital, Hospital Authority, 2Department of Psychology, The Chinese University of Hong Kong, 3Department of Psychiatry, University of Hong Kong, 4Department of Psychiatry, The Chinese University of Hong Kong, 5Department of Psychiatry, Kwai Chung Hospital, Hospital Authority, 6Department of Clinical Psychology, Alice Ho Mui Ling Nethersole Hospital, Hospital Authority, 7Department of Surgery, University of Hong Kong, Hong Kong, People’s Republic of China Background: Methylphenidate (MPH) has been found to be an effective medication for attention-deficit/hyperactivity disorder (ADHD). However, there are neither consistent nor sufficient findings on whether psychiatric comorbidities and associated cognitive functions of ADHD are related to treatment response to MPH in ADHD children.Objectives: This study investigated whether psychiatric comorbidities, IQ, and neurocognitive deficits are related to treatment response to MPH in ADHD children. In some ways, it is preferable to have a drug that the effectiveness of which to a disorder is not affected by its associated cognitive functions and psychiatric comorbidities. On the other hand, it is likely that the baseline symptom severity of ADHD is associated with the effectiveness of MPH treatment on the symptoms post treatment.Methods: A total of 149 Chinese boys (aged 6–12 years) with ADHD, combined type, and normal IQ participated in this study. Assessment of ADHD symptom severity was conducted pre and post MPH treatment, while assessment of psychiatric comorbidities, IQ, and neurocognitive deficits was performed in a non-medicated condition. Treatment response was defined as the ADHD symptom severity post MPH treatment.Results: Results indicated that MPH treatment was effective, significantly improving the ADHD condition. Yet, comorbid disorders, IQ, and neurocognitive deficits were not related to MPH treatment response on ADHD symptoms. These findings indicated that the effectiveness of MPH was not affected by psychiatric comorbidities and associated cognitive functions of ADHD. Instead, as expected, it was the baseline symptom severity that was mainly related to the treatment response, ie, the milder the baseline condition, the better the treatment response.Conclusion: The current findings positively endorse the widespread clinical use of MPH for treating ADHD. It improves the behavioral symptoms of ADHD regardless of varying psychiatric comorbidities, IQ, and neurocognitive deficits. Keywords: ADHD, psychiatric comorbidities, cognitive functions, treatment response, methylphenidate
format	article
author	Chan MH Leung PW Ho TP Hung SF Lee CC Tang CP Cheung KC Ching FY Chan FH Chen LH Garcia-Barcelo M Sham PC
author_facet	Chan MH Leung PW Ho TP Hung SF Lee CC Tang CP Cheung KC Ching FY Chan FH Chen LH Garcia-Barcelo M Sham PC
author_sort	Chan MH
title	Are psychiatric comorbidities and associated cognitive functions related to treatment response to methylphenidate in boys with attention-deficit/hyperactivity disorder?
title_short	Are psychiatric comorbidities and associated cognitive functions related to treatment response to methylphenidate in boys with attention-deficit/hyperactivity disorder?
title_full	Are psychiatric comorbidities and associated cognitive functions related to treatment response to methylphenidate in boys with attention-deficit/hyperactivity disorder?
title_fullStr	Are psychiatric comorbidities and associated cognitive functions related to treatment response to methylphenidate in boys with attention-deficit/hyperactivity disorder?
title_full_unstemmed	Are psychiatric comorbidities and associated cognitive functions related to treatment response to methylphenidate in boys with attention-deficit/hyperactivity disorder?
title_sort	are psychiatric comorbidities and associated cognitive functions related to treatment response to methylphenidate in boys with attention-deficit/hyperactivity disorder?
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/2922c1da2bff49bfb3fde3cafe1bbe4e
work_keys_str_mv	AT chanmh arepsychiatriccomorbiditiesandassociatedcognitivefunctionsrelatedtotreatmentresponsetomethylphenidateinboyswithattentiondeficithyperactivitydisorder AT leungpw arepsychiatriccomorbiditiesandassociatedcognitivefunctionsrelatedtotreatmentresponsetomethylphenidateinboyswithattentiondeficithyperactivitydisorder AT hotp arepsychiatriccomorbiditiesandassociatedcognitivefunctionsrelatedtotreatmentresponsetomethylphenidateinboyswithattentiondeficithyperactivitydisorder AT hungsf arepsychiatriccomorbiditiesandassociatedcognitivefunctionsrelatedtotreatmentresponsetomethylphenidateinboyswithattentiondeficithyperactivitydisorder AT leecc arepsychiatriccomorbiditiesandassociatedcognitivefunctionsrelatedtotreatmentresponsetomethylphenidateinboyswithattentiondeficithyperactivitydisorder AT tangcp arepsychiatriccomorbiditiesandassociatedcognitivefunctionsrelatedtotreatmentresponsetomethylphenidateinboyswithattentiondeficithyperactivitydisorder AT cheungkc arepsychiatriccomorbiditiesandassociatedcognitivefunctionsrelatedtotreatmentresponsetomethylphenidateinboyswithattentiondeficithyperactivitydisorder AT chingfy arepsychiatriccomorbiditiesandassociatedcognitivefunctionsrelatedtotreatmentresponsetomethylphenidateinboyswithattentiondeficithyperactivitydisorder AT chanfh arepsychiatriccomorbiditiesandassociatedcognitivefunctionsrelatedtotreatmentresponsetomethylphenidateinboyswithattentiondeficithyperactivitydisorder AT chenlh arepsychiatriccomorbiditiesandassociatedcognitivefunctionsrelatedtotreatmentresponsetomethylphenidateinboyswithattentiondeficithyperactivitydisorder AT garciabarcelom arepsychiatriccomorbiditiesandassociatedcognitivefunctionsrelatedtotreatmentresponsetomethylphenidateinboyswithattentiondeficithyperactivitydisorder AT shampc arepsychiatriccomorbiditiesandassociatedcognitivefunctionsrelatedtotreatmentresponsetomethylphenidateinboyswithattentiondeficithyperactivitydisorder
_version_	1718399678824841216

Are psychiatric comorbidities and associated cognitive functions related to treatment response to methylphenidate in boys with attention-deficit/hyperactivity disorder?

Ejemplares similares